

03-16-09

AFF/TEK
Docket No.: 089918.021302

Filed via Express Mail No. ED946273671US on March 12, 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No: 10/597,930

Confirmation No: 7979

Filed: December 4, 2006

Art Unit: 1623

For: COMPOSITIONS AND METHODS
USED TO TREAT ACNE AND
CANDIDA

Examiner: Layla D. Bland

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.98, 1.555 and 1.933 the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information in this communication and the attached PTO/SB/08 be expressly considered during the above-captioned proceedings, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

U.S. Patent Documents

3983140
4231938
4346227
4444784
4450171
4681893
4739073
4804770
4946830
4970150
5015632
5082859
5102888
5118673
5260440
5273995
5441943
5502199
5569483
5620961
5626856
5773425
5786342
5834442
5861142
5869289
5891861
5895784
5908761

5995100
6190657
6329422
6413494
6417173
6550807
6642205
6645946
6652856
6756362
6756401
6787521
6844354
6893637
6912230
6936618
6964761
6986995
7166299
5490991
5498702
5547945
5681923
5831052
6258383
6274566
6423314
6680306
6875451

U.S. Patent Publications

20010026807
20010036483
20020044967
20020058061
20020068077
20020107222
20030013681

20040091503
20040023925
20040254419
20050154042
20060057131
20060067927
20060024357

Foreign Patent Documents

GB 2029220
WO 84/04041
EP 0382210
JP 04288017
WO 93/08810 A1
JP 05124956
EP 0595133 A
WO 96/19243 A
EP 0721784
DE 19524515 A

WO 2004/024183
WO 2006/017417
WO 00/07624
WO 00/62076
WO 02/057284
WO 02/076474
WO 02/26262
WO 03/000118
EP 0 888 776

Non-Patent References

PALOMINO, E., "Carbohydrate Handles as Natural Resources in Drug Delivery", Advanced Drug Delivery Reviews, Amsterdam, NL, vol. 13, 1994, pages 311-323
OUCHI et al., "Synthesis and Cytotoxic Activity of Oxiiodized Galactomannan/ADR Conjugate", JMS Pure Applied Chemistry, 1997, A34(6), pages 975-989
KATZUNG, Betran, Basic and Clinical Pharmacology, 1998, 7 th Edition, Appleton & Lange, pages 881-912
MEY A. et al., "The Animal Lectin Galectin-3 Interacts with Bacterial Lipopolysaccharides Via Two Independent Sites", The Journal of Immunology, 1996, Vol. 156, pages 1572-1577
PAN, Z.K. et al., "A Recombinant Listeria Monocytogenes Vaccine Expressing a Model Tumour Antigen Protects Mice Against Lethal Cell Challenges and Causes Regression of Established Tumours", Nat. Med., , 1995, Vol. 1, No. 5, pages 471-477
PLATT, D. et al, "Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin", Journal of National Cancer Institute, 1992, Vol. 84, No. 6, pages 438-442
KLYSOV, A.A. et al, "Preclinical Studies of Anticancer Efficacy of 5-Fluorouracil When Coadministered with the 1,4-beta-D-Galactomannan", Preclinica., September/October 2003, vol. 1, No. 4, pages 175-183
PLATT, D. et al, "Davanat-A Modified Branched Galactomannan Enhances Chemotherapeutics: Reflections on Manufacturing, Pre-Clinical Studies and Clinical Trials", Abstract No. 1 of papers, 227 th ACS National Meeting, Anaheim, CA, Publisher: American

Chemical Society, Washington, D.C., March 28-April 1, 2004

HETZEL et al, "Different Effects of Growth Factors on Proliferation and Matrix Productions of Normal and Fibrotic Human Lung Fibroblasts", Lung, 2005, 183, pages 225-237

LOU et al., Pharmaceutical Research, 2002, Vol. 19, pages 396-402

SEO et al., "Preparation of Multifunctional Low Molecular Weight Chitosan and Its Application in Cosmetics", SOFW-Journal, 128, January 9, 2002, pages 46-51

International Search Report Mailed in December 14, 2005 in connection with PCT/US2005/004430

The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories, pages 981-995

ODA, "Anti-Tumor Activity of Xanthan Gum" Yakuri to Chiryo, 1985, Vol. 13, NO. 10, pages 5743-5750

VAN DER BOONGARD et al., "Successful Rescue with Leucovorin and Thymidine in a Patient with High-Dose Methotrexate Induced Acute Renal Failure", Cancer Chemotherapy and Pharmacology, 2001, Vol. 47, pages 537-540

JAKOBSEN et al., "Dose-Effect Relationship of 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer", Acto Oncologica, 2002, Vol. 41, pages 525-531

2006 Chemical Abstracts Catalog, published 2005 by Chemical Abstracts Service, page 52

Avery' Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd Edition, 1987, Edited by Trevor M. Speight, Chapter VIII, pages 255-282

International Search Report Mailed in April 13, 2005 in connection with PCT/US2004/028883

International Search Report and Written Opinion Mailed in August 8, 2006 in connection with PCT/US05/27187

OOSTERVELD et al, "Characterization of Arabinose and Ferulic Acid Rich Pectic Polysaccharides and Hemicelluloses from Sugar Beet Pulp", Carbohydrate Research, 200, 328, pages 185-197

"Synthesis and Cytotoxic Activity of Oxidized Galactomannan/ADR Conjugate, J.M.S. Pure Applied Chemistry, 1997, A34(6), pages 975-989

LOPEZ E, Del Pozo V, Miguel T, Sastre B, Seoane C, Civantos E, Llanes E, Baeza ML, Palomino P, Cardaba B, Gallardo S, Manzarbeitia F, Zubeldia JM, Lahoz C. Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J Immunol. 2006 Feb 1;176 (3): 1943-50.

- FITZNER B, Walzel H, Sparmann G, Emmrich J, Liebe S, Jaster R. Galectin-1 is an inductor of pancreatic stellate cell activation. *Cell Signal.* 2005 Oct;17(10):1240-7. Epub 2005 Jan 21.
- MAEDA N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, Okuyama H, Hirabayashi J, Kasai K, Yoshizato K. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. *J Biol Chem.* 2003 May 23;278(21):18938-44. Epub 2003 Mar 19.
- YAMAZAKI K, Kawai A, Kawaguchi M, Hibino Y, Li F, Sasahara M, Tsukada K, Hiraga K. Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21(WAF1/Cipl/Sdil), and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CC14. *Biochem Biophys Res Commun.* 2001 Feb 2;280(4):1077-84
- WANG L, Friess H, Zhu Z, Frigeri L, Zimmermann A, Korc M, Berberat PO, Buchler MW. Galectin-1 and galectin-3 in chronic pancreatitis. *Lab Invest.* 2000 Aug;80(8):1233-41
- KASPER M, Hughes RC. Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. *J Pathol.* 1996 Jul;179(3):309-16
- WERT, Susan, Mitsuhiro Yoshida, Ann Marie LeVine, Machiko Ikegami, Tracy Jones, Gary F. Ross, James H. Fisher, Thomas R. Korfhagen, and Jeffrey A. Whitsett, Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. *PNAS*, May 2000; 97: 5972 - 5977
- BROWN, Michael, et al., A Receptor-Mediated Pathway for Cholesterol Homeostasis. Nobel Lecture, December 9, 1985
- ENDO A. The discovery and development of HMG-CoA reductase inhibitors. *J. Lipid Research*, 33, 1992, 1569-1582.
- ENDO A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. *J. Med. Chem.*, 28, No. 4, 401-405, 1985.
- ENDO A., Kuroda M., and Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites, having hypocholesterolemic activity. *FEBS Letters*, 72, 323-326, 1976.
- HOLGATE G.A., Ward W.H.J., and McTaggart F. Molecular mechanism for inhibition of 3-hydroxy3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. *Biochem. Soc. Transactions*, 31, Part 3, 528-531, 2003.
- ENDO A., Kuroda M., and Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterologenesis produced by *Penicillium citrinum*. *J. Antibiot. (Japan)*, 29, 1346-1348, 1976.
- HMG-CoA Reductase Inhibitors. General Monograph, Canadian Pharmacists Association, 2002.

- WEBER C., Erl W., Weber K.S.C., and Weber P.C. HMG-CoA reductase inhibitors decrease CD11 b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. *J. Am. Coll. Cardiol.*, 30, 1212-1217, 1997.
- DESAGER J.P., Normans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. *Clin. Pharmacokinetics*, 31, 348-371, 1996.
- BELLOSTA S., Via D., Canavesi M., Pfister P., Fumagalli R., and Paoletti R. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. *Arterioscler. Thromb. Vasc. Biol.*, 18, 1671-1678, 1998.
- AKIRA K., Amano M., Okajima F., Hashimoto T., and Oikawa S. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits. *Biol. Pharm. Bull.* 29, No. 1, 75-81, 2006.
- BERNICK C., Katz R., Smith N.L., Rapp S., Bhadelia R., Carlson M., Kuller L. Statins and cognitive function in the elderly. *Neurology*, 65, 1388-1394, 2005.
- MASSE I., Bordet R., Deplanque D., Al Khedr A., Richard F., Libersa C., and Pasquier F. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. *J. Neurology, Neurosurgery, and Psychiatry*. 76, 1624-1629, 2005.
- MIIDA T., Takahashi A., Tanabe, N., Ikeuchi, T. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression? *Current Opinion in Lipidology*. 16, No. 6, 619623, 2005.
- BARLOGIE, B. et al., "Etoposide, Dexamethasone, Cytarabine, and Cisplatin in Vincristine, Doxorubicin, and Dexamethasone-Refactory Myeloma", *Journal of Clinical Oncology*, Vol. 7, No 10 (1989).
- BELKA, C. et al. "Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL." *Oncogene* 20, 2190-2196 (2001).
- BERGENHEIM, A.T. et al. "Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans." *Br. J. Cancer* 67, 358-361 (1993).
- BIANCO, C. et al. "Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor." *Clin. Cancer Res.* 8, 3250-3258 (Oct. 2002).
- BONAVIDA, B. et al. "Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review)." *Int. J. Oncol.* 15, 793-802 (Oct. 1999).
- CHAUHAN et al., "A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells." *Cancer*

Res, 65: (18), (2005)
CHRISTODOULOU et al. "Anti-proliferate activity and mechanism of action of titanocene dichloride." Br. J. Cancer 77(12), 2088-2097 (1998).
CITRO et al. "c-myc Antisense Oligodeoxynucleotides Enhance the Efficacy of Cisplatin in Melanoma Chemotherapy in Vitro and in Nude Mice." Cancer Res. 58, 283-289 (15 Jan. 1998).
COMICUERET, O. "Linkingcyclins to transcriptional control." Gene 299, 35-55 (2002).
ELEZ, R. et al. "Tumor regression by combination antisense therapy against Plk1 and Bel-2." Oncogene 22, 69-80 (2003).
HERSHBERGER, P.A. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis." Clin. Cancer Res. 7, 1043-1051 (April 2001).
IMAM et al. "Interferon-Alpha Induces bcl-2 Proto-Oncogene in Patients with Neuroendocrine Gut Tumor Responding to its Antitumor Action." Anticancer Res. 17, 4659-4666 (1997).
LIU et al., "Citrus Pectin: Characterization and Inhibitory Effect on Fibroblast Growth Factor - Receptor Interaction." J. Agric. Food Chem. 49:3051-3057 (2001)
MILLER et al. "Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Non-Small Cell Lun. Cancer." J. Clin. Oncol. 18 6 , 1346-1350 (March 2000).
MIZUTANI et al. "Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin." J. Urology 165, 263-270 (Jan. 2001).
MOHAMMAD et al. "The Addition of Bryostatin 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model." Clin. Cancer Res. 6, 4950-4956 (Dec. 2000).
SWANNIE, H. C. et al. "Protein Kinase C Inhibitors." Curr. Oncol. Reports 4(1), 37-46 (Jan. 2002).
TU, Y. et al., "Upregulated Expression of BCL-2 in Multiple Myeloma Cells Induced by Exposure to Doxorubicin, Etoposide, and Hydrogen peroxide Blood, Vol. 88, No 5, 1805-1812 (1996).
WARFIELD, P. R. "Adhesion of Human Breast Carcinoma to Extracellular Matrix Proteins Is Modulated by Galectin-3." Invasion Metastasis 17, 101-112 (1998).
APARICIO, A. "In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates." Leukemia 12, 220-229 (1998).
BALDUS, S.E. et al. "Increased Galactin-3 Expression in Gastric Cancer: Correlations with

- Histopathological Subtypes, Galactosylated Antigens and Tumor Cell Proliferation." *Tumor Biol.* 21, 258-266 (2 Jul 1999).
- BERBERAT, P.O. et al. "Comparative Analysis of Galectins in Primary Tumors and Tumor Metastasis in Human Pancreatic Cancer." *J. Histochem. Cytochem.* 49, 539-549 (2001).
- BIANCO, C. et al. "Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor." *Clin. Cancer Res.* 8, 3250-3258 (Oct. 2002).
- BOLD, R.J. et al. "Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome." *J. Surg. Res.* 100, 11-17 (2001).
- BREWER, C.F. "Binding and cross-linking properties of galectins. *Biochim. Biophys.*" *Acta* 1572, 255-262 (2002).
- BURKE, P.A. et al. "Combined Modality Radioimmunotherapy." *Cancer* 94, 1320-1331 (15 Feb. 2002).
- CAMBY, I. et al. "Galectins are differently expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration." *Brain Pathology* 11, 12-26 (2001).
- CHERAYIL, B.J. et al. "Molecular cloning of a human macrophage lectin specific for galactose." *PNAS* 87, 7324-7328 Sept. 1990.
- CHOUFANI, G. et al. "The Levels of Expression of Galectin-1, Galectin-3, and the Thomsen-Friedenreich Antigen and Their Binding Sites Decrease as Clinical Aggressiveness Increases in Head and Neck Cancers. *Cancer* 86, 2353-2363 (1 Dec. 1999.)"
- CINDOLO, L. et al. "Galectin-1 and Galectin-3 Expression in Human Bladder Transitional-Cell Carcinomas." *Int. J. Cancer* 84, 39-43 (1999).
- COOPER, D.N.W. "Galectinomics: finding themes in complexity." *Biochim Biophys Acta* 1572, 209-231 (2002).
- COQUERET, O. "Linking cyclins to transcriptional control." *Gene* 299, 35-55 (2002).
- COTTER, F.E. "Controlling The Mitochondria! Gatekeeper for Effective Chemotherapy." *British Journal of Haematology* 111:52-60 (2000)
- DANGUY, A. et al. "Galectins and cancer." *Biochim. Biophys Acta* 1572, 285-293 (2002).
- Definition of apoptosis and cytotoxicity, Wikipedia
- DEL BINO, G. et al. "Altered Susceptibility of Differentiating HL-60 Cells to Apoptosis Induced by Antitumor Drugs." *Leukemia* 8, 281-288 (Feb. 1994).

DIPAOLA, R.S. and Aisner, J. "Overcoming bcl 2-and p53 Mediated Resistance in Prostate Cancer." *Seminars in Oncology* 26, 112-116 (Feb. 1999).

EASTMAN, A. and Rigas, J.R. "Modulation of Apoptosis Signaling Pathways and Cell Cycle Regulation." *Seminars in Oncology* 26, 7-16 (Oct. 1999).

FAN, W. et al. "In vitro evaluation of combination chemotherapy against human tumor cells." *Oncology Reports* 5, 1035-1042 (1998).

FRANCOIS, C. et al. "Galectin-1 and Galectin-3 Binding Pattern Expression in Renal Cell Carcinomas." *Am. J. Clin. Pathol.* 112, 194-203 (1999).

GBC 590 SafeScience Clinical Data. R&D Focus Drug News, DRUGNL. an:1186 (2001)

GLINSKY, V.V. et al. "Effects of Thomsen-Friedenreich Antigen-specific Peptide P-30 on B-Galactoside-mediated Homotypic Aggregation and Adhesion to the Endothelium of MDA-MB 435 Human Breast Carcinoma Cells." *Cancer Res.* 60, 2584-2588 (15 May 2000).

GLINSKY, V.V. et al. "The Role of Thomsen-Friedenreich Antigen in Adhesion of Human Breast and Prostate Cancer Cells to the Endothelium." *Cancer Res.* 61, 4851-4857 (15 June 2001).

GONG, H.C. et al. "The NH₂ Terminus of Galectin-3 Governs Cellular Compartmentalization and Functions in Cancer Cells." *Cancer Res.* 59, 6239-6245 (15 Dec. 1999).

GRANT, S. and Dent, P. "Rational integration of agents directed at novel therapeutic targets into combination chemotherapeutic regimens." *Curr. Opin. Investigational Drugs* 2, 1600-1605 (2001),

GROSS, A. "The role of BCL-2 family members in apoptosis." Published by the Department of Biological Regulation, Weizmann Institute of Science, Israel.

HARA, I. et al. "Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity." *Int. J. Oncol.* 17, 1213-1218 (2000).

HERNANDEZ, J.D. and Baum, L.G. "Ah, sweet mystery of death! Galectins and control of cell fate." *Glycobiology* 12, 127R-136R (2002).

HORTOBAGYI, G.N. "Recent Progress in the Clinical Development of Docetaxel (Taxotere)." *Seminars in Oncology* 26, 32-36 (June 1999).

HRDLICKOVA, E. et al. "Detection of galectin-3 in tear fluid at disease states and immunohistochemical and lectin histochemical analysis in human corneal and conjunctival Ophthalmol. 85, 1336-1340 (2001).

INOHARA, H. et al. "Expression of Galectin-3 in Fine-Needle Aspirates as a Diagnostic Marker Differentiating Benign from Malignant Thyroid Neoplasms." *Cancer* 85, 2475-2484 (1 June

1999).

INUFUSA, H. et al. "Role of galectin-3 in adenocarcinoma liver metastasis." *Int. J. Oncol.* 19, 913-919 (2001).

LURISCI, I. et al., "Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients," *Clinical Cancer Research* 6:1389-1393 (2000)

JENSEN-JAROLIM, E. et al. "Anti-Galectin-3 IgG Autoantibodies in Patients with Crohn's Disease Characterized by Means of Phage Display Peptide Libraries." *J. Clin. Immunol.* 21(5), 348-356 (2001).

JOHNSON, K. R. et al. "Antagonistic Interplay between Antimitotic and G1-S Arresting Agents Observed in Experimental Combination Therapy." *Clin. Cancer Res.* 5, 2559-2565 (Sept. 1999).

JULIAO, S. et al. "Galectin-3: A Marker and Diagnostic Aid for Chordoma." Present at the 47th Annual Meeting, Orthopaedic Research Society, page 0846, February 25-28, 2001, San Francisco, CA.

KARMANOS, Barbara Ann Cancer Institute. "Novel Therapeutic Targets &Therapies." www.karmanos.org/we/research/prostate/novel.html retrieved on 1/27/2003.

KILPATRICK, D. C. "Animal Lectins: a historical introduction and overview." *Biochim. et Biophys..I Acta* 1572, 187-197 (2002).

KIM, Hyeong-Reh Choi et al., "Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells," *Cancer Research* 59:4148-4154 (1999)

KIM, R. et al. "A pitfall in the survival benefit of adjustment chemotherapy for node and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein (Review)." *Int. J. Oncol.* 19, 1075-1080 (2001).

KLASS, R. J. et al. "Eradication of Human Non Hodgkin's Lymphoma in SCID Mice by BCL 2 Antisense Oligonucleotides Combine with Low-Doses Cyclophosphamide." *Clin. Cancer Res.* 6, 2492 2500 (June 2000).

LEFFLER, H. et al. "Specificity of Binding of Three Soluble Rat Lung Lectins to Substituted and Unsubstituted Mammalian B Galactosides." *J. Biol. Chem.* 261(22), 10119-10126 (5 Aug. 1986).

LIM, Y. et al. "Identification of autoantibodies associated with systemic lupus erythematosus. Biochem." *Biophys. Res. Comm.* 295, 119-124 (2002).

LIN, H.M. et al., "Galectin-3 Mediates Genistein-induced G2/M Arrest and Inhibits Apoptosis," *Carcinogenesis* 21(11):1941-1945 (2000)

LINEHAN, W. M. "Inhibition of Prostate Cancer Metastasis: a Critical Challenge Ahead. *J. Nat.*" *Cancer Inst.* 87(5), 331-332 (1 March 1995).

LIU, F.-T. et al. "Intracellular functions of galectins." *Biochim et Biophys Acta* 1572, 263-273 (2002).

LOPES DE MENEZES, D. E. et al. "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin." *Clin. Cancer Res.* 6, 2891-2902 (July 2002).

LOTZ, M. M. et al. "Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma." *PNAS* 90, 3466-3470 Aid (1993).

MAJLESSIPOUR, F. "The Combination Regimen of Idarubicin and Taxotere is Effective Against Human Drug-resistant Leukemic Cell Lines." *Anticancer Res.* 22, 1361-1368 (2002).

MATARRESE P., et al., (Abstract) "Galectin-3 Overexpression Protects from Apoptosis by Improving Cell Adhesion Properties," *Int. Cancer* 85(4):545-554 (2000)

MATARRESE, P., et al. "Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis." *FEBS Letters* 473, 311-315 (2000).

MAZUREK et al., "Phosphorylation of the B-Galactoside-binding Protein Galectin-3 Modulates Binding to its Ligands," *The Journal of Biological Chemistry* 275(46):36311-36315 (2000)

MEY, A. et al. "Expression of the galactose binding protein Mac-2 by human melanoma cell-lines." *Cancer Letters* 81, 155-163 (1994).

NAKAMURA, M. et al. "Involvement of galectin-3 expression in colorectal cancer progression and metastasis." *Int. J. Oncol.* 15, 143-148 (1999).

Novocastra Laboratories, Ltd. "Galectin-3: mouse monoclonal antibody NCL-GAL3."

OHANNESIAN, D. W. et al. "Carcinoembryonic Antigen and Other Glycoconjugates Act as Ligands for Galectin-3 in Human Colon Carcinoma Cells." *Cancer Res.* 55, 2191-2199 (15 May 1995).

Oncolink: Lilly Oncology Treatment Options. www.oncolink.com/treatment/section.cfm retrieved on 2/12/2003.

ORLANDI, F. et al. "Galectin 3 Is a Presurgical Marker of Human Thyroid Carcinoma." *Cancer Res.* 58, 3015 3020 (15 July 1998).

PERILLO, N. L. "Galectins: versatile modulators of cell adhesion, cell proliferation, and cell (1998).

PIENTA, K.J. et al. "Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin." *J. Nat. Cancer Inst.* 87(5), 348-353 (1 March 1995).

PUGLIESE, G. "The Diabetic Milieu Modulates the Advanced Glycation End Product Receptor

Complexes in the Mesangium by Inducing or Upregulating Galectin-3 Expression." *Diabetes* 49, 1249-1257 (July 2000).

RABINOVICH, G.A. "Role of galectins in inflammatory and immunomodulatory processes. *Biochim. Biophys.*" *Acta* 1572, 274-284 (2002).

RABINOVICH, G.A. et al. "Recombinant Galectin-1 and Its Genetic Delivery Suppress Collagen-induced Arthritis via T Cell Apoptosis." *J. Exp. Med.* 190(3), 385-397 (2 Aug. 1999).

RABINOVICH, G.A. et al. "The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 express." *Cancer Immunol. Immunother.* 50, 597-(2002).

RABINOVICH, G.A. et al., "Galectins and Their Ligands: Amplifiers, Silencers or Tuners of the Inflammatory Response?" *Trends in Immunology* 23(6):313-320 (2002)

RAYNAUD, F. I. "Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice." *J. Pharmacol Exp. Therapeutics* 281(1), 420-427 (1997).

RUDIN, C. M. et al. "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small cell lung cancer." *Ann. Oncol.* 13, 539-545 (2002).

RUITER, G.A. et al. "Alkyl-Lysophospholipids as Anticancer Agents and Enhancers of Radiation-Induced Apoptosis." *Int. J. Radiation Oncol. Biol. Phys.* 49(2), 415-419 (2001).

SANO, H. et al. "Human Galectin-3 Is a Novel Chemoattractant for Monocytes and Macrophages." *J. Immunol.* 165, 2156-2164 (2000).

SAUER, G. et al. "New Molecular Targets of Breast Cancer Therapy." *Strahlenther. Onkol.* 178(3), 123-133 (2002).

SHIH, C. et al. "Cryptophycins: A Novel Class of Potent Antimitotic Antitumor Depsipeptides." *Curr. Pharm. Des.* 7, 1259-1276 (2001).

SÖRME, P. et al. "Low Micromolar Inhibitors of Galectin-3 Based on 3-Derivatization of N-Acetyl lactosamine." *ChemBioChem* 3, 183-189 (2002).

TAKAHASHI, T. et al. "Mechanisms of the apoptotic activity of CI-F-araA in a human T-ALL cell line, CCRF-CEM." *Cancer Chemother Pharmacol.* 50, 193-201 (2002).

TENTORI, L. et al. "Role of Wild-Type p 53 on the Antineoplastic Activity of Temozolomide Alone or Combined with Inhibitors of Poly(ADP-Ribose) Polymerase." *J. Pharmacol. Exp. Therapeutics* 285(2), 884-893 (1998).

TORTORA, G. et al. "Combined Blockade of Protein Kinase A and Bcl-2 by Antisense Strategy Induces Apoptosis and Inhibits Tumor Growth and Angiogenesis." *Clin. Cancer Res.* 7,

2537-2544 (Aug. 2001).

TORTORA, G. et al. "Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy." *Ann. N.Y. Acad. Sci.* 968, 139-147 (2002).

TU, S.-M. et al. "Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells." *Cancer Letters* 93, 147-155 (1995).

USUDA, J. et al. "Increased Cytotoxic Effects of Photodynamic Therapy in IL-6 Gene Transfected Cells via Enhanced Apoptosis." *Int. J. Cancer* 93, 475-40 (2001).

VIVAT-HANNAH, V. et al. "Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel)." *Cancer Res.* 61(24), 8703-8711 (15 Dec. 2001).

Webster's New World Dictionary, 3rd. ed., Simon & Schuster (New York, 1988) page 433.

XIA, F. "The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer." *Semin. Radiat. Oncol.* 12(4), 296-304 (2002).

XU, X.-C. et al. "Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms." *Int. J. Oncol.* 17, 271-276 (2000).

YAMAMOTO, D. et al. "Synergistic action of apoptosis induced by eicosapentaenoic acid and TNP-470 on human breast cancer cells." *Breast Cancer Res. Treatment* 55, 149-160 (1999).

YAMAOKA, K. et al. "Overexpression of A fl-Galactoside Binding Protein Causes Transformation of Balb3T3 Fibroblast Cells." *Biochem. Biophys. Res. Comm.* 179(1), 272-279 (30 Aug. 1991).

YANG, R.-Y. et al. "Expression of galectin-3 modulates T-cell growth and apoptosis." *PNAS* 93, 6737-6742 (June 1996).

YOSHII, T. et al. "Galectin-3 Phosphorylation is Required for Its Anti-apoptotic Function and Cell Cycle Arrest." *J. Biol. Chem.* 277(9), 6852-6857 (1 March 2002).

ZENG, S. et al. "In Vitro Evaluation of Schedule-dependent Interactions between Docetaxel and Doxorubicin against Human Breast and Ovarian Cancer Cell." *Clin. Cancer Res.* 6, 3766-3773 (Sept. 2000).

ZETTER, "Angiogenesis and tumor metastasis," *Annu. Rev. Med.* 49:407-424 (1998)

ZHU, W.-Q. et al. Rapid Release of Intracellular Galectin-3 from Breast Carcinoma Cells by Fetus. *Cancer Res.* 61, 1869-1873 (1 March 2001).

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/557,120 dated November 20, 2007 by Examiner Patrick T. Lewis

Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/557,120 dated August 28, 2008 by Examiner Patrick T. Lewis

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/108,237 dated October 4, 2004 by Examiner James O. Wilson

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/649,131 dated October 4, 2004 by Examiner James O. Wilson

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/597,930 dated November 30, 2007 by Examiner Shaojia Anna Jiang

Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/597,930 dated December 23, 2008 by Examiner Layla D. Bland

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/649,130 dated October 4, 2004 by Examiner James O. Wilson

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/889,555 dated December 29, 2008 by Examiner Humera N. Sheikh

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 11/182,096 dated September 3 2008 by Examiner Shaojia Anna Jiang

Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/657,508 dated July 18, 2008 by Examiners Eric S. Olson and Shaojia Anna Jiang

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/657,508 dated August 23, 2007 by Examiners Eric S. Olson and Shaojia Anna Jiang

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 10/657,508 dated October 2, 2006 by Examiner Devesh Khare

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/961,681 dated February 26 2002 by Examiner Jose G. Dees

Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/961,681 dated September 9 2002 by Examiner Jose G. Dees

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/818,596 dated June 2, 2003 by Examiner James O. Wilson

Non-Final Office Action from United States Patent and Trademark Office for U.S.S.N. 09/818,596 dated December 19, 2002 by Examiner James O. Wilson

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign and non-patent literature in accordance with 37 CFR 1.98(a)(2).

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Also, the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The Examiner is advised that the following co-pending applications contain subject matter that may be related to the present application. By bringing these applications to the Examiner's attention, Applicant does not waive the confidentiality provisions of 35 U.S.C. 122.

Patent/Application Number	Filing Date	Art Unit	Most Recent Office Action
11/182,096	7/15/05	1623	9/3/08
11/659,170	5/14/08	1657	—
10/657,508	3/10/05	1623	7/18/08
12/036,086	2/28/08	—	—
10/889,555	7/12/04	1615	12/29/08
10/597,930	12/14/06	1623	12/23/08
10/557,120	10/30/06	1623	8/28/08


It is submitted that this Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Pursuant to 37 CFR §1.97(c), a fee of \$180 is due with this paper. Please charge our Deposit Account No. 501561 for this and any additional fees due with this paper. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 501561, Docket No. 089918.021702.

Dated: March 12, 2009

Respectfully submitted,

By:


Barry J. Schindler
Registration No. 32,938
Greenberg Traurig LLP
200 Park Avenue
Florham Park, NJ 07932
(973) 360-7944
Attorneys/Agents for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop: Amendment
Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

APPLICANT(S):	David Platt et al.	:	EXAMINER: Layla D. Bland
APPLICATION NO.:	10/597,930	:	GROUP ART UNIT: 1623
FILED:	December 4, 2006	:	DOCKET NO.: 089918.021302
FOR:	COMPOSITIONS AND METHODS USED TO TREAT ACNE AND CANDIDA		

EXPRESS MAIL CERTIFICATE

Express Mail Label No. ED 946273671 US

Date of Deposit: March 12, 2009

I hereby certify that the following attached paper(s) and/or fee

- (1) Information Disclosure Statement with PTO/SB/08 forms and cited references; and
- (2) A self-addressed stamped postcard, return of which is requested to acknowledge receipt of the enclosed documents.

are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 C.F.R. Section 1.10 on the date indicated above and is addressed to the Mail Stop: Amendment; Commissioner for Patents, United States Patent and Trademark Office P.O. Box 1450, Alexandria, VA 22313-1450.

Respectfully submitted,
GREENBERG TRAURIG, LLP


Christine Lucas
Patent Prosecution Paralegal

Dated: March 12, 2009

CORRESPONDENCE:
Barry J. Schindler, Esq.
GREENBERG TRAURIG, LLP
Met Life Building
200 Park Avenue
New York, NY 10166
Tele: (212) 801-9200
Fax: (212) 801-6400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10597930
	Filing Date	2006-12-04
	First Named Inventor	David Platt
	Art Unit	1623
	Examiner Name	Layla D. Bland
	Attorney Docket Number	089918-021302

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).


OR

- That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2009-03-12
Name/Print	Barry Schindler	Registration Number	32,938

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.